News and Events
AptaTargets closes €2.7- million round of funding for new stroke treatment
'la Caixa', throught their venture capital arm Caixa Capital Risc, and Inveready have invested €2.7 million in AptaTargets, which will allow this biopharmaceutical company to complete the preclinical phase and move into phase I and II clinical trials on its first drug candidate (ApTOLL) to treat acute ischemic stroke. Press release
ApToll gets funds from Retos-2015 Program
(Dec, 2015) The Spanish Ministry of Economy and Competiveness has granted AptaTargets with funds from the National Research, Development and Innovation Program oriented to Social Challenges, within the 2013-2016 National Plan for Scientific and Technical Research and Innovation. The ApTOLL project aims to advance in the preclinical development of a molecule based on aptamer technology for acute stroke and myocardial infarction. The consortium is led by the company AptaTargets and are also participating Aptus Biotech, the Neurovascular Research Unit (Complutense University) and the Institute of Biomedical Research (UAM-CSIC). The project is funded by the Ministry of Economy and Competitiveness and funds from the European Union, within the objective of promoting the technological development, innovation and research.
Caixa Capital supports AptaTargets
(May, 2015) AptaTargets has received financial support from Caixa Capital Risc (the Venture Capital from CaixaBank), with the aim of advancing with the development of an innovative therapy based on aptamer technology for treatment of Acute Stroke.
AptaTargets completes the first capital call
(Jan, 2015). AptaTargets has successfully completed the first capital call: with the first injection of capital, the company will carry out the R&D Plan for 2015 which aims to develop preclinical studies (non GLP) to validate candidate efficacy and to determine a first toxicology and pharmacokinetics profile.